Please login to the form below
CML
This page shows the latest CML news and features for those working in and with pharma, biotech and healthcare.
Inside the patient-centricity bubble
There has been some egregious behaviour in the industry in terms of drug pricing, ”he said referring to the net price of CML drugs, which have tripled over the course of
Latest news
-
Pfizer’s leukaemia drug Mylotarg backed for use in EU
Kineret (anakinra) in rare inflammatory condition Still’s disease; and Pfizer’s Bosulif (bosutinib) as a treatment for newly-diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia (CML).
-
FDA’s year-end approvals take annual tally to 46
Meanwhile, Novartis got the go-ahead for new labelling for its chronic myeloid leukaemia (CML drug Tasigna (nilotinib. ... It has become the first and only BCR-ABL tyrosine kinase inhibitor (TKI) to include data about attempting treatment discontinuation
-
Novartis' orphan drug Tasigna wins EU expanded indication
Novartis' orphan drug Tasigna wins EU expanded indication. The CML medication can now treat paediatric patients. ... In the studies, patients - aged two-18 years - with newly diagnosed CML achieved a major molecular response rate of 60% at 12 cycles.
-
Takeda's gamble on Ariad pays off with Alunbrig approval
Iclusig - approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) - has been a slow-grower, largely because of safety concerns and while it has started to gain traction it
-
FDA approval for Kisqali sets up showdown with Ibrance
Novartis has experience of marketing drugs with QT prolongation, a side effect which affects its chronic myeloid leukemia (CML) therapy Tasigna (nilotinib) but has not stopped the drug from becoming a
More from news
Approximately 4 fully matching, plus 58 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2017
With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase
-
Deal Watch May 2016
In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and
-
Seismic shifts: Hepatitis C and payers
Analogues such as Glivec (imatanib) which transformed outcomes in CML need to be utilised to demonstrate that tough investment decisions by payers do pay off.
-
Deal Watch table for December 2014
Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA). ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).
-
Interview: Harvey Berger and Timothy Clackson, Ariad
cancer: chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... treatment. “ CML drugs represent real breakthroughs in treatments of patients who would otherwise be very difficult to treat,”
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Helen Parfitt joins Research Partnership
She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Therapy Watch expands oncology and IBD portfolios
CML is a rare cancer affecting the white blood cells and accounts for only 20% of all leukaemias affecting adults. ... The new CML study will include a panel of Haematologists and Haemato-Oncologists reporting on CML patients every month, including both
-
Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch
expanded its oncology portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Chronic Myeloid Leukaemia (CML) in 2017.
-
Research Partnership
new Chronic Myelogenous Leukaemia (CML) study in the US.
-
Research Partnership
new Chronic Myelogenous Leukaemia (CML) study in the US.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Associate Scientific Director
-
Salary TBC
- Sudler London - Senior Medical Writer
-
Competitive
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Sudler London - Account Director
-
Competitive
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
Subscribe to our email news alerts
- Tox trouble stalls Sosei/Allergan Alzheimer’s drug
- London cancer hub launched by Cancer Research UK
- Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
- Making a Difference - The Future of Pharma
- AZ prepares to file COPD triple, taking on rival GSK
- Controversy grows around GP at Hand service after minister’s endorsement
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
